Next Science Limited (NXSCF)

Market Cap	28.64M
Revenue (ttm)	22.07M
Net Income (ttm)	-9.43M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,094
Average Volume	1,426
Open	0.0950
Previous Close	0.0600
Day's Range	0.0600 - 0.0950
52-Week Range	0.0052 - 0.1492
Beta	1.13
RSI	29.57
Earnings Date	Oct 26, 2025

About Next Science

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: NXSCF

Financial Performance

In 2024, Next Science's revenue was $22.82 million, an increase of 2.87% compared to the previous year's $22.18 million. Losses were -$10.59 million, -34.94% less than in 2023.